Zweig DiMenna Associates LLC Grows Stock Holdings in Natera, Inc. (NASDAQ:NTRA)

Zweig DiMenna Associates LLC grew its stake in shares of Natera, Inc. (NASDAQ:NTRA) by 213.0% in the 3rd quarter, according to its most recent Form 13F filing with the Securities & Exchange Commission. The fund owned 242,625 shares of the medical research company’s stock after acquiring an additional 165,100 shares during the period. Natera accounts for 3.1% of Zweig DiMenna Associates LLC’s holdings, making the stock its 7th largest position. Zweig DiMenna Associates LLC owned about 0.20% of Natera worth $30,801,000 as of its most recent filing with the Securities & Exchange Commission.

A number of other institutional investors also recently made changes to their positions in the company. Farallon Capital Management LLC grew its stake in shares of Natera by 13.6% in the second quarter. Farallon Capital Management LLC now owns 4,460,557 shares of the medical research company’s stock valued at $483,034,000 after acquiring an additional 532,874 shares in the last quarter. First Light Asset Management LLC grew its position in shares of Natera by 295.9% during the 1st quarter. First Light Asset Management LLC now owns 656,708 shares of the medical research company’s stock worth $60,063,000 after purchasing an additional 490,822 shares in the last quarter. AQR Capital Management LLC increased its holdings in shares of Natera by 257.6% during the second quarter. AQR Capital Management LLC now owns 651,523 shares of the medical research company’s stock worth $70,553,000 after purchasing an additional 469,327 shares during the period. Nikko Asset Management Americas Inc. acquired a new stake in shares of Natera in the first quarter valued at approximately $33,938,000. Finally, Sumitomo Mitsui Trust Holdings Inc. acquired a new stake in shares of Natera in the first quarter valued at approximately $33,956,000. Institutional investors own 99.90% of the company’s stock.

Natera Stock Up 0.4 %

Shares of NTRA opened at $119.17 on Friday. The company has a debt-to-equity ratio of 0.34, a quick ratio of 4.01 and a current ratio of 4.14. Natera, Inc. has a 52 week low of $36.90 and a 52 week high of $133.54. The stock has a market capitalization of $14.74 billion, a price-to-earnings ratio of -48.64 and a beta of 1.53. The stock has a fifty day moving average of $123.37 and a 200-day moving average of $111.09.

Natera (NASDAQ:NTRA) last posted its earnings results on Thursday, August 8th. The medical research company reported ($0.30) EPS for the quarter, beating the consensus estimate of ($0.69) by $0.39. The firm had revenue of $413.35 million during the quarter, compared to the consensus estimate of $343.00 million. Natera had a negative return on equity of 36.74% and a negative net margin of 21.47%. The business’s quarterly revenue was up 58.1% on a year-over-year basis. During the same period last year, the company earned ($0.97) earnings per share. As a group, sell-side analysts anticipate that Natera, Inc. will post -1.96 earnings per share for the current fiscal year.

Insider Activity at Natera

In other Natera news, CEO Steven Leonard Chapman sold 4,084 shares of the business’s stock in a transaction that occurred on Monday, July 29th. The shares were sold at an average price of $102.77, for a total transaction of $419,712.68. Following the sale, the chief executive officer now directly owns 206,293 shares of the company’s stock, valued at $21,200,731.61. The trade was a 0.00 % decrease in their position. The transaction was disclosed in a legal filing with the SEC, which can be accessed through this link. In other Natera news, CEO Steven Leonard Chapman sold 4,084 shares of the company’s stock in a transaction dated Monday, July 29th. The stock was sold at an average price of $102.77, for a total value of $419,712.68. Following the sale, the chief executive officer now owns 206,293 shares in the company, valued at approximately $21,200,731.61. The trade was a 0.00 % decrease in their position. The transaction was disclosed in a filing with the SEC, which is accessible through this link. Also, CFO Michael Burkes Brophy sold 496 shares of the firm’s stock in a transaction dated Wednesday, October 23rd. The stock was sold at an average price of $119.09, for a total value of $59,068.64. Following the transaction, the chief financial officer now owns 74,314 shares of the company’s stock, valued at $8,850,054.26. This trade represents a 0.00 % decrease in their ownership of the stock. The disclosure for this sale can be found here. Insiders sold a total of 49,458 shares of company stock worth $5,924,920 in the last quarter. 7.60% of the stock is owned by insiders.

Wall Street Analysts Forecast Growth

A number of equities analysts have commented on the company. Canaccord Genuity Group raised their price objective on Natera from $130.00 to $145.00 and gave the stock a “buy” rating in a research note on Tuesday, August 27th. Morgan Stanley increased their target price on Natera from $125.00 to $132.00 and gave the stock an “overweight” rating in a report on Tuesday, August 13th. Robert W. Baird boosted their price target on Natera from $117.00 to $120.00 and gave the company an “outperform” rating in a research note on Friday, August 9th. UBS Group reduced their price objective on shares of Natera from $160.00 to $145.00 and set a “buy” rating on the stock in a research note on Friday, August 9th. Finally, Piper Sandler restated an “overweight” rating and issued a $150.00 target price on shares of Natera in a research report on Friday, September 13th. One analyst has rated the stock with a sell rating and sixteen have assigned a buy rating to the stock. Based on data from MarketBeat, the company presently has an average rating of “Moderate Buy” and a consensus target price of $124.44.

Natera Company Profile

Natera, Inc, a diagnostics company, develops and commercializes molecular testing services worldwide. Its products include Panorama, a non-invasive prenatal test that screens for chromosomal abnormalities of a fetus, as well as in twin pregnancies; Horizon carrier screening test for individuals and couples determine if they are carriers of genetic variations that cause certain genetic conditions; Vistara single-gene NIPT screens for 25 single-gene disorders that cause severe skeletal, cardiac, and neurological conditions; Spectrum, preimplantation genetic tests for couples undergoing IVF; Anora that analyzes miscarriage tissue from women; Empower, a hereditary cancer screening test; and non-invasive prenatal paternity product, which allows a couple to establish paternity without waiting for the child to be born.